Serum levels of high mobility group box 1 protein and its association with quality of life and psychological and functional status in patients with fibromyalgia

Basit Öğe Kaydı
dc.contributor.authorOktayoglu, Pelin
dc.contributor.authorTahtasiz, Mehmet
dc.contributor.authorBozkurt, Mehtap
dc.contributor.authorEm, Serda
dc.contributor.authorUcar, Demet
dc.contributor.authorYazmalar, Levent
dc.contributor.authorMete, Nuriye
dc.date.accessioned2024-04-24T17:11:24Z
dc.date.available2024-04-24T17:11:24Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: High mobility group box 1 protein (HMGB1) is a proinflammatory cytokine. Previous studies have suggested that HMGB1 can play an important role in the pathogenesis of many rheumatic diseases. The purpose of this study was to investigate the serum levels of HMGB1 in patients with fibromyalgia (FM) and its association with quality of life and psychological and functional status in these patients. Methods: Twenty-nine patients who met the 1990 American College of Rheumatology (ACR) criteria for the classification of FM and 29 healthy controls (HC) were included in the present study. Serum samples were collected from both the patients and the HC, and HMGB1 levels were measured by enzyme-linked immunosorbent assay (ELISA). The Fibromyalgia Impact Questionnaire (FIQ) was used to assess the disease severity and functional status in patients with FM. Furthermore, the Nottingham Health Profile was used to assess quality of life in all subjects, as well as the Hospital Anxiety and Depression Scale (HADS) to assess depression and anxiety. Results: The serum levels of HMGB1 protein were positively correlated with the FIQ scores in patients with FM (P = 0.002). Mean serum levels of HMGB1 were higher in patients with FM than in HC but this difference was not statistically significant. Conclusion: HMGB1 protein might be a good laboratory-sourced candidate for the assessment of functional status and disease severity in patients with FM.en_US
dc.identifier.doi10.1111/1756-185X.12124
dc.identifier.endpage407en_US
dc.identifier.issn1756-1841
dc.identifier.issn1756-185X
dc.identifier.issue4en_US
dc.identifier.pmid23992259
dc.identifier.scopus2-s2.0-84883464820
dc.identifier.scopusqualityQ3
dc.identifier.startpage403en_US
dc.identifier.urihttps://doi.org/10.1111/1756-185X.12124
dc.identifier.urihttps://hdl.handle.net/11468/17473
dc.identifier.volume16en_US
dc.identifier.wosWOS:000323721600007
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal of Rheumatic Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFibromyalgiaen_US
dc.subjectFunctional Statusen_US
dc.subjectHigh Mobility Group Box 1 Proteinen_US
dc.subjectPsychological Statusen_US
dc.subjectQuality Of Lifeen_US
dc.titleSerum levels of high mobility group box 1 protein and its association with quality of life and psychological and functional status in patients with fibromyalgiaen_US
dc.titleSerum levels of high mobility group box 1 protein and its association with quality of life and psychological and functional status in patients with fibromyalgia
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu